Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Total stock-based compensation expense	$ 2,507	$ 5,007	$ 6,926	$ 9,820
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	1,399	3,844	4,607	7,679
Cost of Revenue [Member]
Total stock-based compensation expense	31		54
Selling and Marketing Expense [Member]
Total stock-based compensation expense	455	591	899	1,216
General and Administrative Expense [Member]
Total stock-based compensation expense	1,674	4,162	5,262	8,164
Research and Development Expense [Member]
Total stock-based compensation expense	347	254	711	440
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	16		28
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	247	215	470	480
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	836	3,313	3,348	6,514
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	66	26	136	97
PAVmed Inc 2014 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	9		16
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	120	161	253	336
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	8	77	164	145
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 97	$ 52	$ 192	$ 107